ArticleFrontiers in medicine2026
Subthreshold micropulse laser for retinal pigment epithelium detachment: subtype-stratified outcomes and predictors of treatment response.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pigment epithelium detachment (PED) arising from various macular diseases can significantly impair visual function. Although subthreshold micropulse laser treatment (SMLT) shows promise for PED, comparative data across subtypes and factors influencing outcomes remain limited. Methods: We included patients with visually significant macular PED who underwent SMLT between January 2017 and April 2023. Visual acuity and PED dimensions were recorded at baseline and follow-up. PEDs were classified as serous (sPED), drusenoid (dPED), or polypoidal (pPED) using fluorescein fundus angiography/indocyanine green angiography and optical coherence tomography. Within-group changes were assessed using paired Results: Forty-two patients (42 eyes; mean age 60.90 years; 59.5% male patients) were included: 27 with sPED, 10 with dPED, and 5 with pPED. Patients with sPED were significantly younger (mean 53.00 years) than those with dPED (77.20) and those with pPED (71.00; Conclusion: SMLT was associated with modest visual and anatomic improvements, with statistically significant PED area reduction observed only in sPED eyes; the absence of a control arm limits causal inference. Baseline BCVA was the strongest predictor of outcomes. Larger controlled studies are needed to establish the efficacy of SMLT across PED subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.